January 23, 2026
ENDOGEN: IVF Stem Cell Breakthrough for Infertility
A 2024 study in the American Journal of Translational Research reveals ENDOGEN, an autologous stem cell therapy, improves endometrial thickness by 2-3 mm and IVF success rates in refractory patients. Led by Dinorah Hernández-Melchor and colleagues, the treatment uses mesenchymal stem cells to enhance oocyte quality and reduce reliance on egg donation.
Key Takeaways
ENDOGEN Enhances Endometrial Thickness for Better IVF Success
ENDOGEN increases endometrial thickness by 2-3 mm, optimizing implantation conditions. This is critical for patients with refractory endometrium who have previously failed IVF attempts.
ENDOGEN Boosts Oocyte Quality in Repeated IVF Failures
By improving endometrial vascularization and cell communication, ENDOGEN supports follicular development. Patients produce healthier embryos, addressing a key challenge in infertility treatment.
ENDOGEN Complements Traditional Fertility Treatments Safely
The therapy integrates with standard ovarian stimulation protocols without requiring donors. Mild risks like injection site inflammation are reported, but risks of rejection are virtually eliminated due to autologous cell use.
ENDOGEN’s Minimal Risks Compared to Allogeneic Stem Cells
Unlike donor-derived stem cells, ENDOGEN uses the patient’s own cells, avoiding immunological complications. This makes it a low-risk option for improving IVF outcomes.
Reducing Egg Donation Dependency with ENDOGEN Stem Cell Therapy
Preliminary results show ENDOGEN increases implantation rates by improving endometrial receptivity. This reduces the need for third-party egg donation in complex infertility cases.
Source: Read full article